Methotrexate Aspire Pharma (Malta) (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption reduces the synthesis of DNA, RNA and proteins, limiting the replication of rapidly dividing cells and dampening abnormal immune responses.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Only a qualified healthcare professional should set the regimen.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal harm and birth defects. It is contraindicated in pregnancy and should not be used by breastfeeding mothers due to potential toxicity to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methotrexate is often considered a first‑line DMARD because of its proven efficacy, oral availability and cost‑effectiveness. Compared with biologic agents, it has a broader safety profile but may require more laboratory monitoring. Choice of therapy depends on disease severity, patient comorbidities and treatment response.

Store the product below 25 °C in its original packaging, protecting it from moisture and direct sunlight. Do not expose the tablets to excessive heat or humidity to maintain potency.

Methotrexate Aspire Pharma is taken orally as directed by the prescriber, usually with water. Depending on the indication, it may be taken once weekly or as part of a specific treatment cycle. Patients should follow the exact instructions provided by their healthcare professional.

Serious risks include severe liver toxicity, bone marrow suppression leading to pancytopenia, pulmonary fibrosis, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Regular monitoring of liver enzymes, blood counts and lung function helps mitigate these risks.

Methotrexate is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, and those with known hypersensitivity to the drug. Caution is also advised for patients with renal impairment or existing blood dyscrasias.